Latest data from Poseida's lead
investigational allogeneic CAR-T program, which is based on the
Company's unique stem cell memory T cell (TSCM)
platform
Company to host conference call on
Saturday, September 28, 2024, at
1 PM ET / 10
AM PT to review the P-BCMA-ALLO1 Phase 1 IMS oral
presentation data
Poseida initiates P-BCMA-ALLO1 Phase
1b clinical trial in patients with
multiple myeloma, generating $20
million payment from Roche
SAN
DIEGO, Sept. 5, 2024 /PRNewswire/ -- Poseida
Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell
therapy and genetic medicines company advancing differentiated
non-viral treatments for patients with cancer and rare diseases,
announced today that new clinical data from an ongoing Phase 1
study of P-BCMA-ALLO1 in patients with relapsed/refractory multiple
myeloma will be presented in an oral session at the 21st
International Myeloma Society (IMS) Annual Meeting, which is being
held in Rio de Janeiro from
September 25-28, 2024. The Company is
developing P-BCMA-ALLO1, an investigational off-the-shelf
allogeneic CAR-T cell therapy enriched for stem cell memory T cells
(TSCM), in partnership with Roche for the treatment of
relapsed/refractory multiple myeloma.
"Despite therapeutic advances, multiple myeloma remains an
incurable hematologic cancer and relapses are common with
BCMA-targeting immunotherapies, such as bispecific T-cell engagers
and autologous CAR-T therapies. As a result, patient-focused,
off-the-shelf therapies are needed that can provide clinical
benefit to patients with relapsed or refractory disease," said
Syed Rizvi, M.D., Chief Medical
Officer of Poseida Therapeutics. "We look forward to presenting the
latest data from our ongoing Phase 1 study of P-BCMA-ALLO1 and its
potential as an 'off-the-shelf' therapy for patients at IMS. We are
also pleased to announce the initiation of the Phase 1b portion of the study, which will allow us
to further explore the promise of this program."
IMS Oral Presentation
- Talk Title: OA – 04: A Phase 1 Study of
P-BCMA-ALLO1, a Non-viral, Allogeneic BCMA Directed CAR-T in
Relapsed/Refractory Multiple Myeloma (RRMM)
- Presenting Author: Bhagirathbhai R. Dholaria, MBBS,
Assistant Professor of Medicine, Department of Medicine, Division
of Hematology and Oncology, Vanderbilt
University Medical Center
- Session: Abstract Session 7
- Presentation Date/Time: Friday,
September 27, 2024, at 5:42 PM-5:54
PM local time (4:42 PM ET /
1:42 PM PT)
- Room: 101 A1-A2
Company-Hosted IMS Webcast and Conference Call
Information:
Poseida will host a webcast and conference call
on Saturday, September 28, 2024, at
1 PM ET / 10
AM PT. The conference call can be accessed by dialing
800-225-9448 or 203-518-9708 (International) with the conference ID
PSTX0928. A live webcast may be accessed using the link here, or by
visiting the Events and Presentations section of the Poseida
website at investors.poseida.com. After the live webcast, the
event will remain archived on the Poseida site for approximately 90
days.
P-BCMA-ALLO1 Phase 1b Clinical
Trial
The Company also announced the initiation of a Phase
1b portion of the ongoing Phase 1
clinical trial of P-BCMA-ALLO1 in patients with multiple myeloma.
As a result of achieving this milestone, Poseida will receive a
$20 million payment from
Roche. Poseida and Roche partnered together on the
P-BCMA-ALLO1 Phase 1b trial design,
which incorporates process improvements and feedback from recently
completed advisory board meetings with leading clinicians. Poseida
will continue to have responsibility for the expanded Phase
1/1b trial, which will be funded by
Roche.
About P-BCMA-ALLO1
P-BCMA-ALLO1 is an allogeneic CAR-T
product candidate licensed to Roche targeting B-cell maturation
antigen (BCMA) for the treatment of relapsed/refractory multiple
myeloma. This allogeneic program includes a VH-based binder that
targets BCMA and clinical data presented at ASH in December
2023 support the Company's belief that T stem cell
(TSCM)-rich allogeneic CAR-Ts have the potential to
offer effective, safe, and reliable treatment addressing unmet
needs in multiple myeloma. Additional information about the Phase 1
study is available at www.clinicaltrials.gov using
identifier: NCT04960579.
About Poseida Therapeutics, Inc.
Poseida Therapeutics
is a clinical-stage biopharmaceutical company advancing
differentiated allogeneic cell therapies and genetic medicines with
the capacity to cure certain cancers and rare diseases. The
Company's pipeline includes investigational allogeneic CAR-T cell
therapies for both solid tumors and hematologic cancers as well as
investigational in vivo genetic medicines that address patient
populations with high unmet medical need. The Company's approach is
based on its proprietary genetic editing platforms, including its
non-viral piggyBac® DNA Delivery System, Cas-CLOVER™ Site-Specific
Gene Editing System, Booster Molecule and nanoparticle gene
delivery technologies, as well as in-house GMP cell therapy
manufacturing. The Company has formed strategic collaborations with
Roche and Astellas to unlock the promise of cell therapies for
cancer patients. Learn more at www.poseida.com and
connect with Poseida on X and LinkedIn.
Forward-Looking Statements
Statements contained
in this press release regarding matters that are not historical
facts are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include statements regarding, among
other things, expected plans with respect to clinical trials,
including timing of regulatory and submissions and approvals and
clinical data updates; potential fees, reimbursements, milestones,
royalty payments and other payments that the Company may receive
pursuant to its collaboration agreements with Roche; anticipated
timelines and milestones with respect to the Company's development
programs and manufacturing activities and capabilities; the
potential capabilities and benefits of the Company's technology
platforms and product candidates, including the efficacy, safety
and tolerability profile of such product candidates; the quote
from Dr. Rizvi; and the Company's plans and strategy with
respect to developing its technologies and product candidates.
Because such statements are subject to risks and uncertainties,
actual results may differ materially from those expressed or
implied by such forward-looking statements. These forward-looking
statements are based upon the Company's current expectations and
involve assumptions that may never materialize or may prove to be
incorrect. Actual results could differ materially from those
anticipated in such forward-looking statements as a result of
various risks and uncertainties, which include, without limitation,
the Company's reliance on third parties for various aspects of its
business; risks and uncertainties associated with development and
regulatory approval of novel product candidates in the
biopharmaceutical industry; the Company's ability to retain key
scientific or management personnel; the fact that interim data from
the Company's clinical trials may change as more patient data
become available and remain subject to audit and verification
procedures that could result in material differences from the final
data; the fact that subgroup data may differ from future results of
the same study once additional data has been received; and the
other risks described in the Company's filings with
the Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. The Company undertakes no obligation
to update such statements to reflect events that occur or
circumstances that exist after the date on which they were made,
except as required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/poseida-therapeutics-to-present-new-clinical-data-from-phase-1-study-of-allogeneic-car-t-p-bcma-allo1-in-patients-with-relapsedrefractory-multiple-myeloma-at-21st-international-myeloma-society-annual-meeting-302239426.html
SOURCE Poseida Therapeutics, Inc.
